Primary Ciliary Dyskinesia Pipeline: Insights into Novel Key Pharma Companies, Growth Prospects and Future Primary Ciliary Dyskinesia Pipeline Landscape

DelveInsight's, "Primary Ciliary Dyskinesia Pipeline Insight, 2022," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Primary Ciliary Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. In the Primary Ciliary Dyskinesia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Ciliary Dyskinesia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Primary Ciliary Dyskinesia Pipeline Insight Report
• DelveInsight's Primary Ciliary Dyskinesia Pipeline analysis depicts the space with 04+ active players working to develop 04+ pipeline therapies.
• The leading Primary Ciliary Dyskinesia Companies are working such as Parion Sciences, ReCode Therapeutics, Translate Bio, Santhera Pharmaceuticals, ethris GmbH, and others.
• Promising Primary Ciliary Dyskinesia Pipeline therapies such as VX-371, Hypertonic Saline, Placebo (0.17% saline), and others.
• The Primary Ciliary Dyskinesia Companies and academics are working to assess challenges and seek opportunities that could influence Primary Ciliary Dyskinesia R&D. The therapies under development are focused on novel approaches to treat/improve Primary Ciliary Dyskinesia.
Recent Developmental Activities in the Primary Ciliary Dyskinesia Pipeline
• Epithelial sodium channel (ENaC) inhibitors are designed to block the sodium channels on the airway surfaces. In pulmonary diseases, such as chronic obstructive pulmonary disease, cystic fibrosis and primary ciliary dyskinesia, where there is a build-up of excessively concentrated mucus, preclinical models have demonstrated that blocking ENaC hydrates the mucus on the lung surface. Hydration of airway mucus restores airway clearance and improves lung function. P-1037 is a novel, long acting ENaC Inhibitor that was well tolerated at the doses tested in multiple clinical trials in healthy volunteers and patients with either cystic fibrosis or primary ciliary dyskinesia. The company has reached an agreement with Vertex Pharmaceuticals, Inc. to reacquire the pulmonary rights to epithelial sodium channel (ENaC) inhibitors developed under a collaboration announced between the parties in 2015. Under this agreement, Vertex is eligible to receive future undisclosed royalties based upon commercial success. FDA has also Granted Orphan Drug Designation, Fast Track Designation and Rare Pediatric Disease Designation to Parion Sciences P-1037 Inhalation Solution for the Treatment of Primary Ciliary Dyskinesia.

Request for Sample to know which pharma company is expected to be at the forefront in the coming years, Primary Ciliary Dyskinesia Pipeline Outlook Report @ https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Primary Ciliary Dyskinesia Overview

Primary Ciliary dyskinesia (PCD) is usually an autosomal recessive genetic condition in which the microscopic organelles (cilia) in the respiratory system have defective function. Ciliary dysfunction prevents the clearance of mucous from the lungs, Paranasal sinuses and middle ears. Bacteria and other irritants in the mucous lead to frequent respiratory infections. Symptoms often begin shortly after birth and can include coughing, gagging, choking and lung atelectasis (neonatal respiratory distress). Affected individuals often experience chronic sinus, middle ear and lung infections as well as chronic coughing, excess mucus and hearing loss.

Primary ciliary dyskinesia is diagnosed definitively through examination of lung or sinus tissue obtained from a biopsy or through genetic testing. Specific structural defects that are present in these tissues can be detected under an electron microscope. Airway clearance therapy is used to keep the lung tissue healthy for as long as possible. This therapy may include routine washing and suctioning of the sinus cavities and ear canals. Antibiotics, bronchodilators, steroids and mucus thinners (mucolytics) are also used to treat PCD.

Primary Ciliary Dyskinesia Emerging Drugs: Profile
• P 1037: Parion Sciences
Primary Ciliary Dyskinesia Pipeline Therapeutics Assessment
There are approx. 4+ key companies which are developing the therapies for Primary Ciliary Dyskinesia. The companies which have their Primary Ciliary Dyskinesia drug candidates in the most advanced stage, i.e. Phase II include, Parion Sciences

Find out more about Contagiosum treatment drugs, Contagiosum Clinical Trials Analysis @ https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Primary Ciliary Dyskinesia Pipeline Report Assessment
• Primary Ciliary Dyskinesia Pipeline Product Profiles
• Primary Ciliary Dyskinesia Therapeutic Assessment
• Primary Ciliary Dyskinesia Pipeline Assessment
• Inactive drugs assessment
• Primary Ciliary Dyskinesia Unmet Needs

Scope of the Primary Ciliary Dyskinesia Pipeline Report
• Coverage- Global
• Primary Ciliary Dyskinesia Companies- Parion Sciences, ReCode Therapeutics, Translate Bio, Santhera Pharmaceuticals, ethris GmbH, and others
• Primary Ciliary Dyskinesia Pipeline therapies- VX-371, Hypertonic Saline, Placebo (0.17% saline), and others.
Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Primary Ciliary Dyskinesia drugs?
• How many Primary Ciliary Dyskinesia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary Ciliary Dyskinesia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Primary Ciliary Dyskinesia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Primary Ciliary Dyskinesia and their status?
• What are the key designations that have been granted to the emerging drugs?

Download Sample PDF Report for Contagiosum clinical trials advancements @ https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

.

Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions

This release was published on openPR.